Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer

被引：1
作者：
Wen, Zhu [1 ,2 ]
Li, Qinghua [1 ]
Hu, Guangmo [1 ]
机构：
[1] First Peoples Hosp Hefei, Dept Urol, Hefei 230061, Anhui, Peoples R China
[2] Anhui Med Univ, Affiliated Hosp 1, Dept Urol, Hefei 230022, Anhui, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICAL RESEARCH | 2024年 / 29卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Prostate cancer; PCa; Enzalutamide; Resistance; CBX2; HISTONE MODIFICATIONS; IDENTIFICATION; CELLS;
D O I：
10.1186/s40001-024-02021-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Enzalutamide (Enz) is commonly utilized as the initial treatment strategy for advanced prostate cancer (PCa). However, a notable subset of patients may experience resistance to Enz, resulting in reduced effectiveness. Utilizing Gene Expression Omnibus (GEO) databases, we identified CBX2 as a crucial factor in mediating resistance to Enz, primarily due to its inhibitory effect on the P53 signaling pathway. Silencing of CBX2 using small interfering RNA (siRNA) led to elevated levels of P53 expression in LNCaP cells. This indicates that CBX2 may have a critical effect on PCa Enz resistance and could serve as a promising therapeutic target for individuals with Enz resistance.
引用
收藏
页数：12
相关论文
共 46 条
  • [1] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    Arora, Vivek K.
    Schenkein, Emily
    Murali, Rajmohan
    Subudhi, Sumit K.
    Wongvipat, John
    Balbas, Minna D.
    Shah, Neel
    Cai, Ling
    Efstathiou, Eleni
    Logothetis, Chris
    Zheng, Deyou
    Sawyers, Charles L.
    [J]. CELL, 2013, 155 (06) : 1309 - 1322
  • [2] Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation
    Asberry, Andrew Michael
    Liu, Sheng
    Nam, Hye Seung
    Deng, Xuehong
    Wan, Jun
    Hu, Chang-Deng
    [J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 5873 - 5885
  • [3] Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
    Beltran, Himisha
    Prandi, Davide
    Mosquera, Juan Miguel
    Benelli, Matteo
    Puca, Loredana
    Cyrta, Joanna
    Marotz, Clarisse
    Giannopoulou, Eugenia
    Chakravarthi, Balabhadrapatruni V. S. K.
    Varambally, Sooryanarayana
    Tomlins, Scott A.
    Nanus, David M.
    Tagawa, Scott T.
    Van Allen, Eliezer M.
    Elemento, Olivier
    Sboner, Andrea
    Garraway, Levi A.
    Rubin, Mark A.
    Demichelis, Francesca
    [J]. NATURE MEDICINE, 2016, 22 (03) : 298 - 305
  • [4] Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis
    Buonerba, Carlo
    Ferro, Matteo
    Dolce, Pasquale
    Crocetto, Felice
    Verde, Antonio
    Lucarelli, Giuseppe
    Scafuri, Luca
    Facchini, Sergio
    Vaia, Angelo
    Marinelli, Alfredo
    Terracciano, Daniela
    Montella, Liliana
    Longo, Nicola
    Imbimbo, Ciro
    Mirone, Vincenzo
    Di Lorenzo, Giuseppe
    De Placido, Sabino
    Sonpavde, Guru
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 151
  • [5] CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression
    Chen, Haojie
    Dong, Keqin
    Ding, Jie
    Xia, Jia
    Qu, Fajun
    Lan, Fuying
    Liao, Haihong
    Qian, Yuhang
    Huang, Jiacheng
    Xu, Zihan
    Gu, Zhengqin
    Shi, Bowen
    Yu, Mingming
    Cui, Xingang
    Yu, Yongjiang
    [J]. CANCER LETTERS, 2024, 587
  • [6] Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7
    Chen, Haojie
    Luo, Jia
    Chen, Shaojun
    Shi, Bowen
    Zheng, Xiaocui
    Ji, Haiying
    Zhang, Xiaoqian
    Yin, Yujia
    Du, Kun
    Ding, Jie
    Yu, Yongjiang
    [J]. CELL DEATH DISCOVERY, 2022, 8 (01)
  • [7] The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone
    Chen, Haojie
    Shi, Bowen
    Wu, Yanyuan
    Qian, Yuhang
    Zhou, Jiatong
    Zhang, Xi
    Ding, Jie
    Yu, Yongjiang
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (04) : 749 - 756
  • [8] Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy
    Cheng, Qing
    Butler, William
    Zhou, Yinglu
    Zhang, Hong
    Tang, Lu
    Perkinson, Kathryn
    Chen, Xufeng
    Jiang, Xiaoyin ''Sara''
    McCall, Shannon J.
    Inman, Brant A.
    Huang, Jiaoti
    [J]. EUROPEAN UROLOGY, 2022, 81 (05) : 446 - 455
  • [9] Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer
    Clermont, Pier-Luc
    [J]. EPIGENOMICS, 2023, 15 (02) : 75 - 87
  • [10] Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
    Clermont, Pier-Luc
    Crea, Francesco
    Chiang, Yan Ting
    Lin, Dong
    Zhang, Amy
    Wang, James Z. L.
    Parolia, Abhijit
    Wu, Rebecca
    Xue, Hui
    Wang, Yuwei
    Ding, Jiarui
    Thu, Kelsie L.
    Lam, Wan L.
    Shah, Sohrab P.
    Collins, Colin C.
    Wang, Yuzhuo
    Helgason, Cheryl D.
    [J]. CLINICAL EPIGENETICS, 2016, 8 : 1 - 14
12345